CTOs on the Move

ZestDentalSolutions

www.zestdent.com

 
ZEST Dental Solutions has been manufacturing overdenture implant attachment systems as a global leader and being one of the top dental implant manufacturers for over forty years.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.zestdent.com
  • 2875, Loker Avenue East
    Carlsbad, CA USA 92010
  • Phone: 800.262.2310

Executives

Name Title Contact Details

Similar Companies

Stonewood Village Pharmacy

Stonewood Village Pharmacy is a Fort Smith, AR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Charleston Laboratories Inc

Charleston Laboratories Inc is a Charleston, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Rx Systems

Rx Systems is a Saint Charles, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Oramed

Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology. Oramed is seeking to transform the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which is being evaluated in two pivotal Phase 3 studies and has the potential to be the first commercial oral insulin capsule for the treatment of diabetes. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule (ORMD-0901).

Ascentage Pharma

Ascentage Pharma is a globally-focused, clinical-stage biopharmaceutical company developing novel small molecule therapies for cancers, hepatitis B and age-related diseases. Based on breakthrough technology from the University of Michigan, the Company`s expertise is in designing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death, in cancers. Ascentage has built a rich pipeline of six clinical candidates, including a novel, highly potent Bcl-2/Bcl-xL inhibitor, APG-1252, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors.